Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 4% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price rose 4% during trading on Friday . The company traded as high as $11.94 and last traded at $11.89. Approximately 147,689 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 1,470,866 shares. The stock had previously closed at $11.43.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They set a “sell” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock’s 50 day moving average price is $29.00 and its 200-day moving average price is $24.59. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Institutional Trading of Tonix Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth $40,000. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $72,000. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Jane Street Group LLC lifted its position in shares of Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock worth $548,000 after buying an additional 1,635,119 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after buying an additional 1,855,907 shares during the last quarter. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.